Benign breast papilloma: Is surgical excision necessary?
benign breast
breast papilloma
breast papilloma excision
breast papilloma management
Journal
The breast journal
ISSN: 1524-4741
Titre abrégé: Breast J
Pays: United States
ID NLM: 9505539
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
02
07
2019
revised:
05
09
2019
accepted:
06
09
2019
pubmed:
16
10
2019
medline:
22
6
2021
entrez:
16
10
2019
Statut:
ppublish
Résumé
In many centers internationally, current standard of care is to excise all papillomas of the breast, despite recently reported low rates of upgrade to malignancy on final excision. The objective of this study was to determine the upgrade rate to malignancy in patients with papilloma without atypia. A retrospective review of a prospectively maintained database of all cases of benign intraductal papilloma in a tertiary referral symptomatic breast unit between July 2008 and July 2018 was performed. Patients with evidence of malignancy or atypia on core biopsy and those with a history of breast cancer or genetic mutations predisposing to breast cancer were excluded. One hundred and seventy-three cases of benign papilloma diagnosed on core biopsy were identified. Following exclusions, the final cohort comprised of 138 patients. Mean age at presentation was 51. Mean follow-up time was 9.6 months. The most common symptom was a lump (40%). Of the 124 patients who underwent excision, three had ductal carcinoma in situ and there were no cases of invasive disease, giving an upgrade rate to malignancy of 2.4%. Upgrade to other high-risk lesions (atypical lobular and ductal hyperplasia and lobular carcinoma in situ) was demonstrated in 15 cases (12.1%). Benign papilloma was confirmed in 100 cases (81.5%), and 6 (4.8%) had no residual papilloma found on final excision. Twelve patients (8.7%) were managed conservatively. Of those, one later went on to develop malignancy. Patients with a diagnosis of benign papilloma without atypia on core biopsy have a low risk of upgrade to malignancy on final pathology, suggesting that observation may be a safe alternative to surgical excision. Further research is warranted to determine which patients can be safely managed conservatively.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
705-710Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
Richter-Ehrenstein C, Tombokan F, Fallenberg EM, Schneider A, Denkert C. Intraductal papillomas of the breast: diagnosis and management of 151 patients. Breast. 2011;20(6):501-504.
Shiino S, Tsuda H, Yoshida M, et al. Intraductal papillomas on core biopsy can be upgraded to malignancy on subsequent excisional biopsy regardless of the presence of atypical features. Pathol Int. 2015;65(6):293-300.
Nayak A, Carkaci S, Gilcrease MZ, et al. Benign papillomas without atypia diagnosed on core needle biopsy: experience from a single institution and proposed criteria for excision. Clin Breast Cancer. 2013;13(6):439-449.
Pareja F, Corben AD, Brennan SB, et al. Breast intraductal papillomas without atypia in radiologic-pathologic concordant core-needle biopsies: Rate of upgrade to carcinoma at excision. Cancer. 2016;122(18):2819-2827.
Swapp RE, Glazebrook KN, Jones KN, et al. Management of benign intraductal solitary papilloma diagnosed on core needle biopsy. Ann Surg Oncol. 2013;20(6):1900-1905.
Jaffer S, Bleiweiss IJ, Nagi C. Incidental intraductal papillomas (<2 mm) of the breast diagnosed on needle core biopsy do not need to be excised. Breast J. 2013;19(2):130-133.
Tatarian T, Sokas C, Rufail M, et al. Intraductal papilloma with benign pathology on breast core biopsy: to excise or not? Ann Surg Oncol. 2016;23(8):2501-2507.
Jaffer S, Nagi C, Bleiweiss IJ. Excision is indicated for intraductal papilloma of the breast diagnosed on core needle biopsy. Cancer. 2009;115(13):2837-2843.
Rizzo M, Linebarger J, Lowe MC, et al. Management of papillary breast lesions diagnosed on core-needle biopsy: clinical pathologic and radiologic analysis of 276 cases with surgical follow-up. J Am Coll Surg. 2012;214(3):280-287.
Han SH, Kim M, Chung YR, et al. Benign intraductal papilloma without atypia on core needle biopsy has a low rate of upgrading to malignancy after excision. J Breast Cancer. 2018;21(1):80-86.
Sydnor MK, Wilson JD, Hijaz TA, Massey HD, Shaw, . de Paredes ES. Underestimation of the presence of breast carcinoma in papillary lesions initially diagnosed at core-needle biopsy. Radiology. 2007;242(1):58-62.
Ahmadiyeh N, Stoleru MA, Raza S, Lester SC, Golshan M. Management of intraductal papillomas of the breast: an analysis of 129 cases and their outcome. Ann Surg Oncol. 2009;16(8):2264-2269.
Wang ZL, Liu G, He Y, Li N, Liu Y. Ultrasound-guided 7-gauge vacuum-assisted core biopsy: could it be sufficient for the diagnosis and treatment of intraductal papilloma? Breast J. 2019.
Weisman PS, Sutton BJ, Siziopikou KP, et al. Non-mass-associated intraductal papillomas: is excision necessary? Hum Pathol. 2014;45(3):583-588.
Silverstein MJ, Lagios MD. Treatment selection for patients with ductal carcinoma in situ (DCIS) of the breast using the University of Southern California/Van Nuys (USC/VNPI) prognostic index. Breast J. 2015;21(2):127-132.
Cignini P, Vitale SG, Laganà AS, Biondi A, La Rosa VL, Cutillo G. Preoperative work-up for definition of lymph node risk involvement in early stage endometrial cancer: 5-year follow-up. Updates Surg. 2017;69(1):75-82.
Kryzhanivska AE, Dyakiv IB, Kyshakevych I. Clinical and immunohistochemical features of primary breast cancer and metachronous ovarian and endometrial tumors. Exp Oncol. 2018;40(2):124-127.
Vitale SG, Rossetti D, Tropea A, Biondi A, Laganà AS. Fertility sparing surgery for stage IA type I and G2 endometrial cancer in reproductive-aged patients: evidence-based approach and future perspectives. Updates Surg. 2017;69(1):29-34.